Completed PHASE1 INTERVENTIONAL 1-arm NCT02324621

Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors

A Continuation Clinical Trial of Every Three-Week Dosing of Oral ONC201 in Patients With Advanced Solid Tumors

Sponsor: National Cancer Institute (NCI)

Conditions Unspecified Adult Solid Tumor

Interventions Oral ONC201 laboratory biomarker analysis pharmacological study

Updated 8 times since 2017 Last updated: May 20, 2019 Started: Feb 20, 2015 Primary completion: Oct 18, 2018 Completion: Oct 23, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02324621, this PHASE1 trial focuses on Unspecified Adult Solid Tumor and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Sep 2018 — Jun 2019 [monthly]

Recruiting PHASE1

▶ Show 3 earlier versions

Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE1
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Feb 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Oncoceutics, Inc.
Rutgers Cancer Institute of New Jersey
Rutgers, The State University of New Jersey

Data source: Rutgers, The State University of New Jersey

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Brunswick, United States